By studying the mechanisms of cell death induced by immune system cells, Pierre Golstein and his team have identified several proteins that are now being talked about! This is particularly the case of the CTLA-4 protein, now targeted in certain cancer immunotherapy strategies.
Currently Inserm research director emeritus, he has worked at the Centre d'Immunologie de Marseille-Luminy (CIML)* since its creation in 1976. He has led several teams and even managed the center for several years.
In 1987, Pierre Golstein and his team were looking for the "weapons" used by certain immune system cells to kill harmful cells circulating in the body, when they discovered the CTLA-4 protein. Years later, James Allison developed a therapeutic approach based on the inhibition of this protein's activity – immunotherapy. Its development was rewarded by the Nobel Prize in Physiology or Medicine 2018.
Inserm unit 1104/CNRS/Aix-Marseille University